Compare Danaher Corporation (DHR) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Danaher Corporation vs BIO-TECHNE Corp — how do they compare? Danaher Corporation trades at $207.26 (market cap $147.18B), while BIO-TECHNE Corp trades at $72.13 (market cap $11.24B). The key difference: Danaher Corporation is far larger — about 13.1× BIO-TECHNE Corp's market cap, and Danaher Corporation pays the higher dividend (0.76%). Which is the better fit depends on your goals.
| DHR | TECH | |
|---|---|---|
Market Cap | $147.18B | $11.24B |
Sector | Health | Health |
52-Week High | $242.05 | $72.29 |
52-Week Low | $161.91 | $43.31 |
Enterprise Value | $169.39B | $11.32B |
Dividend Yield | 0.76% | 0.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Danaher (DHR) trades at $204.76, up 2.37% today, near its pivot point of $203 with bullish technical signals. The company has beaten earnings estimates for three consecutive quarters, with Q3 2026 expected at $1.92 EPS. Revenue for 2025 was $24.57B with a net income margin of 15.95%, though margins have trended down from 22.9% in 2022. Recent news includes the Masimo acquisition approval and a $172.5 million settlement over pandemic-era disclosures (Reuters, 2026-04-23).
Outlook is positive with strong analyst support (69% buy ratings) and a consensus price target of $202.33, slightly below current price. Risks include margin compression, high valuation (P/E 36.5), and integration challenges from acquisitions. Cash flow improved to $2.54B net in 2025 after a dip in 2023-2024, supporting dividend payments and growth initiatives.
Bio-Techne (TECH) trades at $72.29, up 0.54% today, with a bullish technical signal from moving averages and a consensus analyst price target of $71.67. Recent earnings showed mixed results, with a Q4 2025 beat but a Q1 2026 miss. The company maintains strong gross margins at 64.96% but faces declining net income margins, down to 6.01% in 2025. Positive cash flow trends and a pending acquisition by Merck highlight ongoing corporate developments.
Outlook is balanced with growth potential from product innovation and acquisition synergies, but risks include earnings volatility, high valuation multiples, and shareholder litigation over the merger terms. Institutional sentiment is split evenly between buy and hold ratings, reflecting cautious optimism amid execution challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Danaher Corporation
In 1984, Danaher's founders transformed a real estate organization into an industrial-focused manufacturing company. Through a series of mergers, acquisitions, and divestitures, including the Fortive separation in 2016, Danaher now focuses primarily on manufacturing scientific instruments and consumables in three segments: life sciences, diagnostics, and environmental and applied solutions. In late 2019, Danaher separated from its dental business through an initial public offering process, and in early 2020, it acquired GE's Biopharma business, now called Cytiva, which added to its life sciences segment.
Read more on DHR →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
